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Abstract
Background: In sub-Saharan Africa, men living with HIV often start ART at more advanced stages of disease and have higher
early mortality than women. We investigated gender difference in long-term immune reconstitution.
Methods/Principal Findings: Antiretroviral-naı ¨ve adults who received ART for at least 9 months in four HIV programs in sub-
Saharan Africa were included. Multivariate mixed linear models were used to examine gender differences in immune
reconstitution on first line ART. A total of 21,708 patients (68% women) contributed to 61,912 person-years of follow-up. At
ART start,. Median CD4 at ART were 149 [IQR 85–206] for women and 125 cells/mL [IQR 63–187] for men. After the first year
on ART, immune recovery was higher in women than in men, and gender-based differences increased by 20 CD4 cells/mL
per year on average (95% CI 16–23; P,0.001). Up to 6 years after ART start, patients with low initial CD4 levels experienced
similar gains compared to patients with high initial levels, including those with CD4.250cells/mL (difference between
patients with ,50 cells/mL and those with .250 was 284 cells/mL; 95% CI 272–296; LR test for interaction with time p=0.63).
Among patients with initial CD4 count of 150–200 cells/mL, women reached 500 CD4 cells after 2.4 years on ART (95% CI
2.4–2.5) and men after 4.5 years (95% CI 4.1–4.8) of ART use.
Conclusion: Women achieved better long-term immune response to ART, reaching CD4 level associated with lower risks of
AIDS related morbidity and mortality quicker than men.
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Introduction
According to UNAIDS, more than 3.9 million patients were
receiving antiretroviral therapy (ART) in sub-Saharan Africa at the
end of 2009. This represents 37% of those in need of treatment and
an increase of one million patients in one year [1]. Early initiationof
ART in the course of disease is associated with better survival [2,3]
and better long-term immune reconstitution [4,5]. Indeed, in 2009,
the World Health Organization (WHO) raised the recommended
CD4 threshold for ART initiation to 350 cells/mL [1,6].
Immune recovery after ART initiation follows two phases: a
rapid increase during the first months, followed by a slower one
thereafter [7,8,9]. They correspond to different biological
mechanisms: the first phase of rapid CD4 cell increase is linked
to the relapse of pre-trapped CD4 cells [10], while the second
phase corresponds to a proliferation of new CD4 cells, related to
thymus reactivation, which progressively reconstitutes stocks of
CD4 cells [11]. The feasibility of complete reconstitution remains
unknown, as do influencing factors.
Most of large cohort studies describing long-term immune
reconstitution have been performed in North American cohorts
[12,13]. In sub-Saharan Africa, the gender differences at ART
start are important. In these settings, more women than men are
infected [14,15], as the majority of infections happen through
heterosexual transmission. Furthermore, men are frequently
underrepresented in ART cohorts, and they initiate ART at a
more advanced stage of the disease with a lower CD4 cell counts.
[16,17,18] In addition, they experience higher early mortality
compared with women [17,19,20,21].
This study explored gender differences in immune reconstitu-
tion after the first 9 months of ART, to focus on the second phase
of immune reconstitution, in four sub-Saharan African HIV
programs supported by Me ´decins Sans Frontie `res (MSF).
Methods
Data Analysis and Study Population
In collaboration with national Ministries of Health, MSF began
providing free HIV care and antiretroviral therapy (ART) in four
programs in Malawi, Uganda, and Kenya between March 2001
and July 2002. A standardized surveillance system was imple-
mented to collect routine demographic, clinical, and treatment
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Gdata (FUCHIA software, Epicentre, Paris, France). Data consis-
tency checks were implemented to ensure the data quality.
The databases used for the analysis were locked on 30
November 2009. ART initiation was based on 2003 and 2006
WHO recommendations. Patients received non-nucleoside reverse
transcriptase inhibitor-based first-line therapy in the form of fixed-
dose combinations. Adherence support was provided by trained
counsellors prior to ART start and during follow-up on treatment.
CD4 cell counts were measured every 6 or 12 months, depending
on the program, initially using manual methods (Dynabeads,
Dynal Biotech SA, Compie `gne, France), and since mid-2003 with
semi-automated techniques (Cyflow counter, Partec, Mu ¨nster,
Germany).
Patients were included in the study if they (a) had initiated ART
in one of the MSF-supported programs, (b) were aged 15 years or
older, (c) were ART-naı ¨ve at the time of therapy start, (d) received
ART for at least 9 months (Figure 1), (e) had complete information
about baseline covariates and (f) had at least one CD4 count after
9 months of ART. We included patients at 9 months after ART
start because we wanted all the CD4 measures taken at one year to
be included, which can sometimes be taken a few months before or
after; thus the 9th month was chosen as the inclusion benchmark.
The last CD4 measurement considered was the one collected at
end of follow-up, at switch to second-line therapy, at transfer out
from the program, or closest to time of death, whichever occurred
first.
Study Definitions and Statistical Methods
Loss to follow-up was defined as the absence of a clinical visit for
at least 9 months (among patients who did not die or were not
transferred out of the program) as patients had up to 6 months
between two follow-up appointments. Second-line therapy was
defined as a protease inhibitor-containing regimen associated with
a concomitant change of at least one nucleoside reverse
transcriptase inhibitor, as described previously in other studies
[22].
For each patient, the initial CD4 cell count was the
measurement taken between 3 months before and 1 month after
ART start. If more than one measurement was taken, the closest to
ART start was considered.
CD4 cell counts were described using medians and interquartile
ranges (IQR). CD4 response to ART was the main outcome
variable. Random intercept and coefficient mixed linear models
with a second-degree natural polynomial of time [23,24] were used
to model long-term immune reconstitution and investigate
differences by gender. Random effects characterize between-
subject variations whereas fixed effects represent the mean value of
a coefficient within the cohort. These models take into account the
correlation between CD4 measures within each individual.
Factors considered in adjusted models were time on ART,
initial CD4 categories (,50, 50–99, 100–149, 150–199, 200–249,
$250 cells/mL), body mass index (BMI) (,16, 16–16.99, 17–
17.99, $18 kg/m
2) at ART start, WHO clinical stage at ART
start (stages 1 to 4), age at ART start (,30, 30–50, .50 years old),
and HIV program. Likelihood ratio (LR) tests and Wald tests for
association were used with a significance level of 0.05.
Predicted evolution of mean CD4 counts over time since ART
start were plotted, stratified by initial CD4 levels and gender. For
female and male patients included in each CD4 cell strata, the
mean time to reach a threshold of 500 cells/mL was predicted. The
corresponding 95% CI were estimated using the delta method
[25]. Data were analyzed using Stata 11 (Stata Corp., College
Station, Texas, USA).
Figure 1. Patient data inclusion flow chart.
doi:10.1371/journal.pone.0031078.g001
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collected, patient monitoring data from the programmes that
Me ´decins Sans Frontie `res is running in partnership with the local
ministry of health for more than 10 years. The data were de-
identified before we accessed them. Verbal consent for use of
monitoring data is routinely obtained from patients at first
consultation, The study protocol and the consent procedure were
approved by the Comite ´ de Protection des Personnes d’Ile de
France (Ref 10,032), Paris, France.
Results
Patient Characteristics at ART Initiation
Of 39,103 patients who ever received ART in the four HIV
programs, 12,946 met the inclusion criteria (Figure 1) and
contributed 33,622 person-years at risk to the analysis. Patient
median follow-up time since ART start were 2.77 years [IQR
1.86–4.17] for women and 2.64 [IQR 1.74–3.91] for men.
Patients treated in the Malawian cohort represented 52% of
eligible patients (Table 1). Women accounted for 69% of patients.
At ART start, median age was 36 years [IQR 30; 42]. Among
them, 19% of women and 24% of men were classified WHO
clinical stage 4. Median initial CD4 count was 141 cells/mL [IQR
77–200], and were higher in women [149 cells/mL; IQR 85–206]
than in men [125 cells/mL; IQR 63–187].
At ART start, median BMI for women and men were 20.2
kg/m
2 [IQR 18.4–22.3] and 19.5 kg/m
2 [IQR 18.0–21.1],
respectively.
At the end of follow-up, 8,878 women (91%) and 3,638 men
(89%) patients were alive and receiving care, 206 men (5%) and
349 women (4%) had been lost to follow-up, 80 men (2%) and 229
women (3%) transferred to other programs. Among the study
population 84 men (2%) and 119 women (1%) had died, and 60
men (1%) and 129 women (1%) had initiated second-line
treatment.
Observed CD4 Response in Women and Men
Median CD4 cell counts increased with time on ART (Figure 2).
The difference between men and women CD4 response also
increased with time on ART. At 1 year of ART, women had a
median CD4 count of 336 cells/mL [IQR 230–466], compared
with 268 cells/mL [IQR 185–387] in men. At 6 years of ART,
median CD4 cell count for women and men were 585 cells/mL
[IQR 399–735] and 412 cells/mL [IQR 250–551], respectively.
Among those who initiated ART with initial CD4 cell count below
50 cells/mL, 134 (15%) women and 127 (19%) men failed to reach
a CD4 count of 100 cells/mL after one year on ART.
Modelling Long-Term CD4 Response in Women and Men
Detailed results of the model to explore the association between
gender and CD4 recovery among patients followed up for more
than 9 months on ART are presented in Table 2. From the 21,708
patients meeting the inclusion criteria, 12,946 patients with
complete information on all the covariates at baseline and at least
one CD4 measure after 9 months on ART contributed to the
analysis.
CD4 count increased regularly during the first 6 years after
ART start, with a progressive slowing of immune reconstitution
with time on ART.
Women experienced better reconstitution than men, after
accounting for all the variables included in the model. After 1
year on ART, women had CD4 count 40 cells/mL (95% CI 34–46)
higher than men, with a yearly average increase of 20 CD4 cells/
mL higher than men (95% CI 16–23, P,0.0001).
Intervals between initial CD4 strata remained constant over
time, as there was no interaction between initial CD4 and time on
ART (LR test for interaction with time, P=0.63). Patients with
higher initial CD4 count reached higher CD4 levels after ART
start. For example, 1 year after ART start, patients who initiated
ART with CD4 count 100–150 cells/mL had a CD4 count on
average 107 cells/mL higher than patients with initial count ,50
cells/mL (95% CI 98–117). This difference increased with higher
initial CD4 levels and was 284 cells/mL (95% CI 272–296) for
patients with initial CD4 of 250 cells/mL or more compared to
those with ,50 cells/mL (LR test for trend, P,0.001).
Age was also associated with immune reconstitution. Patients
younger than 30 years old when they initiated ART had mean
CD4 count 52 cells/mL (95% CI 42–62) higher than those aged
more than 50 years, one year after ART start (LR test, P,0.001).
Associations with initial BMI and WHO clinical stage were less
strong and did not reach statistical significance when the other
variables were accounted in the model.
After 3 years of ART, women and men who had initial CD4
count 100–149 cells/mL reached 475 cells/mL (95% CI 468–482)
and 388 cells/mL (95% CI 379–397), respectively (Figures 3 & 4).
After 6 years of ART, the same group of patients reached 608
cells/mL (95% CI 594–621) and 467 cells/mL (95% CI 449–484),
Table 1. Study population characteristics at ART start,
Uganda, Kenya, and Malawi, 2001–2009.
Women (%) Men (%) Total (%)
N=8,878 N=4,068 N=12,946
HIV program
Homa-Bay, Kenya 1,320 (15.1) 616 (15.1) 1,936 (15)
Mathare, Kenya 861 (9.4) 384 (9.4) 1,245 (10)
Chiradzulu, Malawi 4,501(48.9) 1,989 (48.9) 6,490 (50)
Arua, Uganda 2,196 (26.5) 1,079 (26.5) 3,275 (25)
Age (years)
.50 666 (7.5) 603(14.8) 1,269 (10)
30–50 5,469 (61.6) 2,963 (72.8) 8,432 (65)
,30 2,743 (30.9) 502 (12.3) 3,245 (25)
Clinical stage
Stage 1 1,369 (15.4) 497 (12.2) 1,866 (14)
Stage 2 2,006 (22.6) 770 (18.9) 2,776 (21)
Stage 3 3,832 (43.2) 1,833 (43.2) 5,665 (44)
Stage 4 1,671 (18.8) 968 (23.8) 2,639 (20)
BMI (kg/m
2)
,16 482 (5.4) 217 (5.3) 699 (5)
16–16.99 524 (5.9) 259 (6.4) 2,776 (6)
17–17.99 807 (9.1) 532 (13.1) 5,665 (10)
$18 7,065 (79.6) 3,060 (75.2) 10,125 (78)
CD4 (cells/mL)
,50 1,166 (13.1) 812 (20.0) 1,978 (15)
50–99 1,548 (17.4) 826 (20.3) 2,374 (18)
100–149 1,728 (19.5) 781 (19.2) 2,509 (19)
150–199 1,985 (22.4) 838 (20.6) 2,823 (22)
200–249 1,540 (17.4) 572 (14.1) 2,112 (16)
§250 911 (10.3) 239 (5.9) 1,150 (9)
BMI, body mass index.
doi:10.1371/journal.pone.0031078.t001
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cell count, the higher the level of CD4 count was achieved, and
these differences continued over time.
For predicted mean time from ART start to reach CD4 500
cells/mL (Table 3), women with initial count ,50 cells/mL needed
5.8 years (95% CI 5.5–6.1), while men with the same initial CD4
count were unable to attain this CD4 level. Those men with pre-
treatment CD4 count 200–249 cells/mL reached this threshold at
3.2 years (95% CI 3.0–3.4) after ART start whereas it would take
only 1.8 years (1.7–1.9) to women.
Discussion
In this multisite analysis of four large sub-Saharan African HIV
programs, long-term immune response up to 6 years after ART
start was higher in women compared with men,, independently of
characteristics at initiation.
The gender-based difference in immune reconstitution de-
scribed here has inconsistently been found in previous studies in
resource-rich countries, some studies showing a better female
immune reconstitution [26,27] whereas two literature reviews
indicated that most of the studies did not find any viroimmuno-
logical difference between men and women [28,29].
In resource-limited settings, studies showing worse male
reconstitution are more common. In Cameroon and in China,
two studies recently showed male poorer immune reconstitution
even after initial patients characteristics were accounted for in the
analysis. [30,31]. In another large multicentric study in sub-
Saharan Africa, a gender difference in immune reconstitution was
found, but the difference was explained by baseline characteristics
[32]. In Senegal, a cohort study found a borderline gender effect
which disappeared when viral load and baseline CD4 levels were
integrated in the model. [4] At last, a recent cohort study in
Tanzania found gender differences in mortality, rates of loss of
follow-up or side effects in men but failed to find a significant
difference in immune reconstitution after 3 months of ART [33].
Our study confirmed that gender differences in immune
reconstitution remained even when baseline factors are included
the model. We also showed that this difference increased with time
on ART up to 6 years after initiation. Furthermore, we quantified
this difference to show that after 6 years on ART, it reached 140
CD4 cells/mL. When we estimated the time on ART required to
reach 500 CD4 cells/mL, we found that men remained much
longer under this threshold, known to be associated with higher
morbidity [2,34] and mortality [34].
Behavioural, biological factors or a combination of both could
explain this difference. First, it is known that men living with HIV
usually initiate ART at more advanced stages of disease, resulting
in higher mortality [19,20,21] highlighting gender differences in
health seeking behaviours. Therefore, one possible reason for this
gender difference in immune reconstitution could also be
behavioural and related to a poorer adherence of men to ART
[31,32]. Decentralization of HIV care in sub-Saharan Africa has
been implemented through primary health facilities, and tradi-
tionally such care has been well attended by women and children
but less so by men. [35] Interventions specifically addressing men’s
needs might be effective to improve treatment outcomes in this
patient population. However, we could not verify this hypothesis
as adherence and viral load were not routinely monitored in our
cohorts.
Nevertheless, another explanation needs to be explored,
reflecting a possible biological explanation. It is known that
women have higher physiological CD4 levels compared to men
[35,36,37] and some studies also underlined the effect of male
hormones on the thymic function [37]. Therefore, this gender
difference in immune reconstitution could also be linked to a
higher potential for women to regenerate their CD4 lymphocytes
stock on ART.
We lack of information on women previously exposed to
‘‘prevention to mother to child transmission’’ treatment. Previous
exposure to ART (like single dose nevirapine) might underestimate
the difference between men and women. The underlining
Figure 2. Observed median CD4 cell counts after ART start, by gender, Uganda, Kenya, and Malawi, 2001–2009. N=12,946 patients,
33,622 person-years.
doi:10.1371/journal.pone.0031078.g002
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would be more likely to be resistant to ART and thus to have a
non optimal immune response. However, recent evidences seem to
minimise this influence. [36]
Gender differences in long-term survival outcomes need to be
explored and linked to this observed difference in immune
reconstitution.
CD4 gains up to 6 years after ART start were similar regardless
of the initial CD4 level. We demonstrated for the first time in sub-
Saharan African countries that patients who started ART with
CD4 count over 250 cells/mL achieved similar CD4 gains up to 6
years after ART initiation than those who initiated at lower CD4
levels. If the influence of initial CD4 level on future reconstitution
was well known [4,8,12,13,38,39], such levels of reconstitution for
patients who initiated ART at high CD4 levels had never been
observed previously in sub-Saharan settings. This finding supports
the theory that patients may have the same reconstitution potential
regardless of baseline CD4. We need to evaluate if complete
reconstitution could be feasible if patients were initiated ART at
even earlier stage.
This study suggests that long-term CD4 recovery is independent
of the level of CD4 cells at ART start, and patients who initiated
ART at earlier stages of disease spend shorter time below the
threshold of 500 CD4 cells/mL, which is associated with high
Table 2. Associations between gender and other factors and mean CD4 response to ART.
N (%) Total: 12,946
Adjusted difference in mean
CD4 in cells/mL (95% CI)
Adjusted mean CD4
change per year in
cells/mL (95% CI) P-value
Time (year) 65 (60–69) ,0.001*
Time squared 26( 26, 25) ,0.001*
Gender6time interaction (female vs
male)
20 (16–23) ,0.001*
Gender ,0.001**
Male 4,068 (31) Reference
{
Female 8,878 (69) 40 (34–46)
Programme ,0.001**
Homa-Bay, Kenya 1,936 (15) Reference
{
Mathare, Kenya 1,245 (10) 272 (283, 260)
Chiradzulu, Malawi 6,490 (50) 231 (239, 222)
Arua, Uganda 3,275 (25) 252 (260, 242)
Age (years) ,0.001**
.50 1,269 (10) Reference
{
30–50 8,432 (65) 21 (12–30)
,30 3,245 (25) 52 (42–62)
Initial clinical stage 0.04**
Stage 1 1,866 (14) Reference
{
Stage 2 2,776 (21) 211 (220, 22)
Stage 3 5,665 (44) 212 (221, 24)
Stage 4 2,639 (20) 211 (220, 22)
Initial BMI (kg/m
2) 0.20**
,16 699 (5) Reference
{
16–16.99 2,776 (6) 214 (230, +1)
17–17.99 5,665 (10) 215 (229, 21)
$18 10,125 (78) 212 (224, 1)
Initial CD4 count (cells/ml) ,0.001**
,50 1,978 (15) Reference
{
50–99 2,374 (18) 46 (36–55)
100–149 2,509 (19) 107 (98–117)
150–199 2,823 (22) 167 (157–176)
200–249 2,112 (16) 207 (197–217)
§250 1,150 (9) 284 (272–296)
*P value from Wald test for association model adjusted for all variables included in the table.
**P value from likelihood ratio test for association from the multivariable linear mixed model adjusted for all variables included in the table.
{214 cells/mL (95% CI 195–233) represents the mean CD4 count after 1 year of ART predicted by the multivariable linear mixed model for the reference level of all the
variables included in the table.
BMI, body mass index.
doi:10.1371/journal.pone.0031078.t002
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would decrease this high-risk period and facilitate the provision of
care in areas suffering from human resources shortages.
Consistent with previous studies, advanced age at initiation was
associated with poorer immune reconstitution [27,43]. This might
relate to greater difficulties to reactivate the thymic function and/
or to poorer sustained adherence achieved by older patients [44].
We decided to study patient immune response after the first 9
months of ART because during the early stages of treatment, the
release of pre-trapped CD4 cells could influence the observed
response [45]. The large number of patients included in this
analysis allowed careful investigation and quantification of the
dose-response effect of initial CD4 counts on immune reconstitu-
tion. Indeed, this study used data from four large operational HIV
programs running for almost a decade, giving strength to our
findings.
Nevertheless, given the definition of inclusion criteria, exclusion
of patients because of incomplete initial characteristics is likely to
Figure 3. Predicted female mean CD4 count after ART start by initial CD4 level, Uganda, Kenya, and Malawi. N=8,878; mixed
multivariate polynomial model.
doi:10.1371/journal.pone.0031078.g003
Figure 4. Predicted male mean CD4 count after ART start by initial CD4 level, Uganda, Kenya, and Malawi. N=4,068; mixed multivariate
polynomial model.
doi:10.1371/journal.pone.0031078.g004
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tion. Indeed, patients with advanced HIV disease have often been
prescribed ART without having initial CD4 count data. Since
these patients were likely to have low initial CD4 count values,
missing values on initial CD4 count did not follow a random
process. Imputation of these missing values was therefore not
recommended. Cohort attrition might also have biased estimates.
Patients who were included in the analysis were those who
survived the first months of ART when mortality is higher. We
analyzed routinely collected data without double entry, which
could not be implemented for cohorts of this size, though
consistency checklists were routinely used to try to reduce data
entry errors.
Concerning the generalization of these findings, MSF support
on these programs needs to be accounted, as these programs might
differ from regular Ministry of Health programs.
In this analysis, we found that women treated for HIV
experienced higher immune reconstitution than men, and patients
who survived after the first 9 months on ART. Reasons for the
gender effect should primarily be investigated through differences
in health-seeking and adherence behaviour and addressed to
improve outcomes among men.
The paper has not been published or submitted for publication
elsewhere. This study was presented at the Conference on
Retrovirus and Opportunistic Infections CROI in Boston (David
Maman, Mar Pujades-Rodriguez, Fabien Subtil, Loretxu Pinoges,
Megan McGuire, Rene ´ Ecochard, Jean-Franc ¸ois Etard. Gender
Differences in Long-term Immune Response to ART and
Mortality: A Cohort Analysis in 4 Sub-Saharan HIV Programs,
CROI Conference, Boston, USA, February 27
th–March 2
nd
2011.).
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